vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and Legacy Education Inc. (LGCY). Click either name above to swap in a different company.

Legacy Education Inc. is the larger business by last-quarter revenue ($19.2M vs $14.7M, roughly 1.3× IRIDEX CORP). On growth, Legacy Education Inc. posted the faster year-over-year revenue change (40.7% vs -69.7%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.

IRIX vs LGCY — Head-to-Head

Bigger by revenue
LGCY
LGCY
1.3× larger
LGCY
$19.2M
$14.7M
IRIX
Growing faster (revenue YoY)
LGCY
LGCY
+110.4% gap
LGCY
40.7%
-69.7%
IRIX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
IRIX
IRIX
LGCY
LGCY
Revenue
$14.7M
$19.2M
Net Profit
$2.0M
Gross Margin
37.2%
Operating Margin
13.3%
Net Margin
10.6%
Revenue YoY
-69.7%
40.7%
Net Profit YoY
46.0%
EPS (diluted)
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
LGCY
LGCY
Q4 25
$14.7M
$19.2M
Q3 25
$12.5M
$19.4M
Q2 25
$13.6M
$18.0M
Q1 25
$11.9M
$18.6M
Q4 24
$12.7M
$13.6M
Q3 24
$11.6M
$14.0M
Q2 24
$12.6M
Q1 24
$11.8M
Net Profit
IRIX
IRIX
LGCY
LGCY
Q4 25
$2.0M
Q3 25
$-1.6M
$2.2M
Q2 25
$-994.0K
$1.2M
Q1 25
$-1.7M
$2.8M
Q4 24
$-834.0K
$1.4M
Q3 24
$-1.9M
$2.1M
Q2 24
$-2.7M
Q1 24
$-3.5M
Gross Margin
IRIX
IRIX
LGCY
LGCY
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
LGCY
LGCY
Q4 25
13.3%
Q3 25
-11.3%
13.9%
Q2 25
-6.9%
11.1%
Q1 25
-1.7%
19.7%
Q4 24
-3.9%
12.2%
Q3 24
-16.1%
19.1%
Q2 24
-20.9%
Q1 24
-28.0%
Net Margin
IRIX
IRIX
LGCY
LGCY
Q4 25
10.6%
Q3 25
-12.6%
11.3%
Q2 25
-7.3%
6.8%
Q1 25
-14.2%
15.2%
Q4 24
-6.6%
10.3%
Q3 24
-16.7%
14.9%
Q2 24
-21.2%
Q1 24
-29.5%
EPS (diluted)
IRIX
IRIX
LGCY
LGCY
Q4 25
$0.15
Q3 25
$-0.09
$0.16
Q2 25
$-0.06
$0.07
Q1 25
$-0.10
$0.21
Q4 24
$-0.05
$0.10
Q3 24
$-0.12
$0.21
Q2 24
$-0.16
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
LGCY
LGCY
Cash + ST InvestmentsLiquidity on hand
$6.0M
$21.1M
Total DebtLower is stronger
$660.3K
Stockholders' EquityBook value
$46.1M
Total Assets
$29.2M
$73.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
LGCY
LGCY
Q4 25
$6.0M
$21.1M
Q3 25
$5.6M
$20.6M
Q2 25
$6.8M
$20.3M
Q1 25
$7.2M
$17.3M
Q4 24
$2.4M
$16.9M
Q3 24
$3.9M
$21.5M
Q2 24
$4.1M
Q1 24
$5.4M
Total Debt
IRIX
IRIX
LGCY
LGCY
Q4 25
$660.3K
Q3 25
$776.9K
Q2 25
$1.4M
Q1 25
$1.0M
Q4 24
$1.0M
$1.1M
Q3 24
$1.4M
$758.2K
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
LGCY
LGCY
Q4 25
$46.1M
Q3 25
$4.7M
$43.7M
Q2 25
$6.1M
$41.0M
Q1 25
$852.0K
$39.3M
Q4 24
$2.1M
$36.4M
Q3 24
$2.6M
$32.6M
Q2 24
$4.2M
Q1 24
$6.5M
Total Assets
IRIX
IRIX
LGCY
LGCY
Q4 25
$29.2M
$73.1M
Q3 25
$28.4M
$72.1M
Q2 25
$31.6M
$69.2M
Q1 25
$34.2M
$67.1M
Q4 24
$29.1M
$62.1M
Q3 24
$30.2M
$50.6M
Q2 24
$31.2M
Q1 24
$34.1M
Debt / Equity
IRIX
IRIX
LGCY
LGCY
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.48×
0.03×
Q3 24
0.53×
0.02×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
LGCY
LGCY
Operating Cash FlowLast quarter
$1.1M
Free Cash FlowOCF − Capex
$512.7K
FCF MarginFCF / Revenue
2.7%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$4.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
LGCY
LGCY
Q4 25
$1.1M
Q3 25
$-1.2M
$1.1M
Q2 25
$-397.0K
$3.0M
Q1 25
$-1.1M
$918.7K
Q4 24
$-1.2M
$659.0K
Q3 24
$-3.1M
$3.2M
Q2 24
$-1.3M
Q1 24
$-1.6M
Free Cash Flow
IRIX
IRIX
LGCY
LGCY
Q4 25
$512.7K
Q3 25
$-1.2M
$809.7K
Q2 25
$-410.0K
$2.9M
Q1 25
$-1.2M
$596.6K
Q4 24
$-1.2M
$466.8K
Q3 24
$-3.1M
$2.9M
Q2 24
Q1 24
$-1.7M
FCF Margin
IRIX
IRIX
LGCY
LGCY
Q4 25
2.7%
Q3 25
-9.4%
4.2%
Q2 25
-3.0%
16.2%
Q1 25
-9.8%
3.2%
Q4 24
-9.8%
3.4%
Q3 24
-26.5%
21.1%
Q2 24
Q1 24
-14.0%
Capex Intensity
IRIX
IRIX
LGCY
LGCY
Q4 25
2.8%
Q3 25
0.1%
1.3%
Q2 25
0.1%
0.5%
Q1 25
0.1%
1.7%
Q4 24
0.1%
1.4%
Q3 24
0.0%
1.7%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
IRIX
IRIX
LGCY
LGCY
Q4 25
0.52×
Q3 25
0.48×
Q2 25
2.45×
Q1 25
0.33×
Q4 24
0.47×
Q3 24
1.52×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons